Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres
详细信息 查看全文
- 作者：Antonio Tursia ; antotursi@tiscali.it" class="auth_mail ; Walter Eliseib ; Marcello Picchioc ; Antonio Pennad ; Piera Giuseppina Leccae ; Giacomo Fortif ; GianMarco Giorgettig ; Roberto Faggianih ; Costantino Zampalettah ; Giorgio Peleccah ; Giovanni Brandimartee
- 关键词：Anti-TNF伪 ; Clinical practice ; Clinical remission ; Crohn's disease ; Histological healing ; Mucosal healing
- 刊名：European Journal of Internal Medicine
- 出版年：June 2014
- 年：2014
- 卷：25
- 期：5
- 页码：485-490
- 全文大小：451 K
文摘
- •
Both Infliximab and Adalimumab are effective in ambulatory Crohn’s disease.
- •
Both Infliximab and Adalimumab are safe in those patients, with low side effects.
- •
Both Infliximab and Adalimumab maintain mucosal healing in those patients.
- •
Histological healing in those patients is very low.